68Ga-DOTATATE

DRUG13 trials

Conditions

ACTHCushing's SyndromeGastrointestinal Neuroendocrine TumorsHead and Neck TumorsHealthy (Controls)Healthy VolunteersHypercalcemiaHyperparathyroidism

Early Phase 1

68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia

NCT01524016

Peking Union Medical College HospitalMesenchymal Tumor, Oncogenic Osteomalacia

Start: 2011-12-31End: 2017-12-31Target: 100Updated: 2017-04-07

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

CompletedNCT01873248

Jonsson Comprehensive Cancer CenterNeuroendocrine Tumors

Start: 2013-08-26End: 2017-06-16Updated: 2024-07-19

68Ga-DOTATATE PET/CT in Neuroendocrine Tumor

NCT04041882

Peking Union Medical College HospitalNeuroendocrine Tumors

Start: 2014-04-01End: 2022-01-30Target: 100Updated: 2019-08-01

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

RecruitingNCT05069220

Peking Union Medical College HospitalNeuroblastoma, Neuroendocrine Tumor, Paraganglioma +1

Start: 2021-09-01End: 2026-12-31Target: 150Updated: 2024-03-01

Phase 1

Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO

NCT04689893

Peking Union Medical College HospitalTumor-Induced Osteomalacia

Start: 2020-03-15End: 2022-03-15Target: 50Updated: 2021-01-05

Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors

RecruitingNCT06056362

Peking Union Medical College HospitalNeuroendocrine Tumors

Start: 2023-03-23End: 2025-03-27Target: 80Updated: 2025-04-02

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

RecruitingNCT06427798

National Cancer Institute (NCI)Gastrointestinal Neuroendocrine Tumors, Paragangliomas, Pheochromocytoma +1

Start: 2025-02-07End: 2039-07-01Target: 66Updated: 2026-03-10

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

RecruitingNCT06479811

National Cancer Institute (NCI)Gastrointestinal Neuroendocrine Tumors, Head and Neck Tumors, Kidney Cancers +3

Start: 2025-08-19End: 2032-01-01Target: 120Updated: 2025-11-25

Phase 2

Studies of Elevated Parathyroid Activity

CompletedNCT00001277

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Hypercalcemia, Hyperparathyroidism, MEN1 +2

Start: 1993-12-15End: 2020-12-23Updated: 2022-06-07

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

RecruitingNCT02019706

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)ACTH, Cushing's Syndrome

Start: 2014-02-12End: 2030-12-31Target: 80Updated: 2026-04-02

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

RecruitingNCT07284589

Akiva MintzHealthy (Controls), Healthy Volunteers, Neuroendocrine (NE) Tumors

Start: 2025-12-11End: 2030-04-30Target: 200Updated: 2025-12-16

Unknown Phase

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

CompletedNCT01879657

Radio Isotope Therapy of AmericaNeuroendocrine Carcinoma

Start: 2013-03-01End: 2017-12-05Updated: 2025-08-06

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

CompletedNCT04069299

H. Lee Moffitt Cancer Center and Research InstituteNeuroendocrine Carcinoma

Start: 2019-09-25End: 2025-06-02Updated: 2026-03-31

Related Papers

Assessment of the diagnostic efficacy and clinical significance of [18F]AlF-NOTA-LM3 PET/CT in patients with well-differentiated neuroendocrine tumors.

2025-08-05

[18F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.

2025-07-28

Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial.

2024-06-159 citations

[18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.

2023-05-0928 citations

Head-to-Head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study.

2022-02-2412 citations

Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study.

2021-06-198 citations